Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]

PMID:
31125062
2.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 May 15. pii: S2213-2600(19)30139-0. doi: 10.1016/S2213-2600(19)30139-0. [Epub ahead of print]

PMID:
31103412
3.

Sentinel lymph node biopsy for management of the N0 neck in oral cavity squamous cell carcinoma.

Loree JT, Popat SR, Burke MS, Frustino J, Grewal JS, Loree TR.

J Surg Oncol. 2019 May 16. doi: 10.1002/jso.25494. [Epub ahead of print]

PMID:
31095734
4.

Hyperprogression with immunotherapy: Is it real?

Popat S.

Cancer. 2019 Apr 15;125(8):1218-1220. doi: 10.1002/cncr.31997. Epub 2019 Feb 15. No abstract available.

PMID:
30768797
5.

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Reck M, Kerr KM, Grohé C, Manegold C, Pavlakis N, Paz-Ares L, Huber RM, Popat S, Thatcher N, Park K, Hilberg F, Barrueco J, Kaiser R.

Future Oncol. 2019 Apr;15(12):1363-1383. doi: 10.2217/fon-2018-0948. Epub 2019 Feb 13.

6.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S.

Ann Oncol. 2019 May 1;30(5):863-870. doi: 10.1093/annonc/mdy474. No abstract available.

PMID:
30715168
7.

Body Extension and the Law: Medical Devices, Intellectual Property, Prosthetics and Marginalisation (Again).

Harmon SHE, Brown A, Popat S, Whatley S, O'Connor R.

Law Innov Technol. 2018 Sep 27;10(2):161-184. doi: 10.1080/17579961.2018.1526853.

8.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available.

9.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.

N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.

10.

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.

Lindsay CR, Shaw EC, Blackhall F, Blyth KG, Brenton JD, Chaturvedi A, Clarke N, Dick C, Evans TRJ, Hall G, Hanby AM, Harrison DJ, Johnston SRD, Mason MD, Morton D, Newton-Bishop J, Nicholson AG, Oien KA, Popat S, Rassl D, Sharpe R, Taniere P, Walker I, Wallace WA, West NP, Butler R, Gonzalez de Castro D, Griffiths M, Johnson PWM.

ESMO Open. 2018 Sep 5;3(6):e000408. doi: 10.1136/esmoopen-2018-000408. eCollection 2018.

11.

Gesture and Movement: Indices of Presence.

Popat S.

In: Banks J, editor. Avatar Assembled: The Social and Technical Anatomy of Digital Bodies. New York (NY): Peter Lang; 2017 Nov 15. No abstract available.

12.

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.

Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE.

Future Oncol. 2018 Oct;14(23):2415-2431. doi: 10.2217/fon-2018-0330. Epub 2018 Jul 6.

13.

pH Dependency in Anode Biofilms of Thermincola ferriacetica Suggests a Proton-Dependent Electrochemical Response.

Lusk BG, Peraza I, Albal G, Marcus AK, Popat SC, Torres CI.

J Am Chem Soc. 2018 Apr 25;140(16):5527-5534. doi: 10.1021/jacs.8b01734. Epub 2018 Apr 17.

PMID:
29649873
14.

Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.

Popat S.

N Engl J Med. 2018 Jan 11;378(2):192-193. doi: 10.1056/NEJMe1714580. No abstract available.

15.

Struggling to be Fit: Identity, Integrity, and the Law.

Harmon SH, Brown A, Popat S, Whatley S, O'Connor R.

Scripted. 2017 Dec;14(2):326-344. doi: 10.2966/scrip.140217.326.

16.

Bodily Extensions and Performance.

Popat S, Whatley S, O'Connor R, Brown A, Harmon S.

Int J Perform Arts Digit Media. 2017 Oct 2;13(2):101-104. doi: 10.1080/14794713.2017.1358525. Epub 2017 Aug 28. No abstract available.

17.

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E.

Eur J Cancer. 2017 Dec;87:75-83. doi: 10.1016/j.ejca.2017.09.033. Epub 2017 Nov 10.

18.

Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience.

Tokaca N, Barth S, O'Brien M, Bhosle J, Fotiadis N, Wotherspoon A, Thompson L, Popat S.

J Thorac Oncol. 2018 Jan;13(1):63-72. doi: 10.1016/j.jtho.2017.09.1958. Epub 2017 Oct 6.

19.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

20.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.

21.

Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.

Tokaca N, Wotherspoon A, Nicholson AG, Fotiadis N, Thompson L, Popat S.

Lung Cancer. 2017 Sep;111:65-68. doi: 10.1016/j.lungcan.2017.07.012. Epub 2017 Jul 11.

22.

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA.

Lung Cancer. 2017 Sep;111:6-11. doi: 10.1016/j.lungcan.2017.06.005. Epub 2017 Jun 15.

23.

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Califano R, Greystoke A, Lal R, Thompson J, Popat S.

Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9. Review.

24.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
25.

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.

Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM.

Clin Lung Cancer. 2018 Jan;19(1):74-83.e11. doi: 10.1016/j.cllc.2017.06.002. Epub 2017 Jun 23.

26.

Is pain relief after vaginal mesh and/or sling removal durable long term?

Jong K, Popat S, Christie A, Zimmern PE.

Int Urogynecol J. 2018 Jun;29(6):859-864. doi: 10.1007/s00192-017-3413-5. Epub 2017 Jul 10. Review.

PMID:
28695345
27.

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S.

Clin Lung Cancer. 2017 Sep;18(5):589-593. doi: 10.1016/j.cllc.2017.03.010. Epub 2017 Mar 22.

28.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6.

29.

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.

Melosky B, Popat S, Gandara DR.

Clin Lung Cancer. 2018 Jan;19(1):42-50. doi: 10.1016/j.cllc.2017.05.019. Epub 2017 Jun 8.

PMID:
28668205
30.

Metastasizing Pleomorphic Adenoma Case Report and Review of the Literature.

Alshagroud R, Kamoh A, Popat SR, Brandwein-Weber M, Aguirre A.

Head Neck Pathol. 2017 Dec;11(4):487-493. doi: 10.1007/s12105-017-0815-0. Epub 2017 May 25. Review.

31.

H2O2 Production in Microbial Electrochemical Cells Fed with Primary Sludge.

Ki D, Popat SC, Rittmann BE, Torres CI.

Environ Sci Technol. 2017 Jun 6;51(11):6139-6145. doi: 10.1021/acs.est.7b00174. Epub 2017 May 17.

PMID:
28485588
32.

Do Statins Improve Survival in Small-Cell Lung Cancer?

Popat S.

J Clin Oncol. 2017 May 10;35(14):1497-1498. doi: 10.1200/JCO.2016.72.0870. Epub 2017 Mar 6. No abstract available.

33.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

34.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
35.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA.

Drugs. 2017 May;77(8):813-827. doi: 10.1007/s40265-017-0732-2. Review.

PMID:
28378229
36.

Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Juan O, Popat S.

Clin Lung Cancer. 2017 Nov;18(6):595-606. doi: 10.1016/j.cllc.2017.03.002. Epub 2017 Mar 14. Review.

37.

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.

Juan O, Popat S.

Ther Adv Med Oncol. 2017 Mar;9(3):201-216. doi: 10.1177/1758834016687262. Epub 2017 Jan 30. Review.

38.

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.

Popat S, Mellemgaard A, Reck M, Hastedt C, Griebsch I.

Future Oncol. 2017 Jun;13(13):1159-1171. doi: 10.2217/fon-2016-0493. Epub 2017 Feb 27.

39.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
40.

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Yap TA, Popat S.

J Thorac Oncol. 2017 Jan;12(1):12-14. doi: 10.1016/j.jtho.2016.10.019. No abstract available.

41.

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

Yap TA, Macklin-Doherty A, Popat S.

Eur J Cancer. 2017 Jan;70:12-21. doi: 10.1016/j.ejca.2016.10.014. Epub 2016 Nov 17. Review.

PMID:
27866095
42.

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

Juan O, Popat S.

Lung Cancer. 2017 Feb;104:131-133. doi: 10.1016/j.lungcan.2016.11.007. Epub 2016 Nov 11. No abstract available.

PMID:
27863911
43.

Tailoring Microbial Electrochemical Cells for Production of Hydrogen Peroxide at High Concentrations and Efficiencies.

Young MN, Links MJ, Popat SC, Rittmann BE, Torres CI.

ChemSusChem. 2016 Dec 8;9(23):3345-3352. doi: 10.1002/cssc.201601182. Epub 2016 Nov 10.

PMID:
27863051
44.

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

Juan O, Yousaf N, Popat S.

Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e1-e4. doi: 10.1016/j.clon.2016.09.007. Epub 2016 Sep 27. No abstract available.

PMID:
27686969
45.

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. No abstract available.

PMID:
27664245
46.

The effect of pH and buffer concentration on anode biofilms of Thermincola ferriacetica.

Lusk BG, Parameswaran P, Popat SC, Rittmann BE, Torres CI.

Bioelectrochemistry. 2016 Dec;112:47-52. doi: 10.1016/j.bioelechem.2016.07.007. Epub 2016 Jul 20.

PMID:
27450427
47.

Relevance of Bisphosphonate Therapy in Osteoporosis and Cancer--No Cause for Alarm in Dentistry.

Moore AE, Renton T, Taylor T, Popat S, Jasani MK.

Dent Update. 2016 Apr;43(3):235-6, 239-40, 242.

PMID:
27439270
48.

Authors' response.

Moore AE, Renton T, Taylor T, Popat S, Jasani MK.

Dent Update. 2016 Jul-Aug;43(6):589-90. No abstract available.

PMID:
29148658
49.

Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies.

Khalifa J, Amini A, Popat S, Gaspar LE, Faivre-Finn C; International Association for the Study of Lung Cancer Advanced Radiation Technology Committee.

J Thorac Oncol. 2016 Oct;11(10):1627-43. doi: 10.1016/j.jtho.2016.06.002. Epub 2016 Jun 23. Review.

50.

Critical transport rates that limit the performance of microbial electrochemistry technologies.

Popat SC, Torres CI.

Bioresour Technol. 2016 Sep;215:265-273. doi: 10.1016/j.biortech.2016.04.136. Epub 2016 May 2. Review.

PMID:
27211921

Supplemental Content

Support Center